Nanoparticles-based multi-adjuvant whole cell tumor vaccine for cancer immunotherapy

Biomaterials

Volumn 34, Issue 33, 2013, Pages 8291-8300

  Liu, Shi Ying ^a,b   Wei, Wei ^a   Yue, Hua ^a   Ni, De Zhi ^a,b   Yue, Zhan Guo ^a,b   Wang, Shuang ^a,b   Fu, Qiang ^a,c   Wang, Yue Qi ^a,b   Ma, Guang Hui ^a   Su, Zhi Guo ^a  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Adjuvant; Cytokine; Nanoparticle; Whole cell tumor vaccine

Indexed keywords

ADJUVANT; ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CELL-PENETRATING PEPTIDE; CYTOKINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTORS; INVIVO EVALUATIONS; TUMOR VACCINES;

MACROPHAGES; NANOPARTICLES; T-CELLS; TUMORS; VACCINES;

CYTOLOGY;

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CELL PENETRATING PEPTIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LACTATE DEHYDROGENASE; NANOPARTICLE; TUMOR VACCINE; UNCLASSIFIED DRUG; WHOLE CELL TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; HISTOLOGY; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; LUNG CANCER; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; UREA NITROGEN BLOOD LEVEL; WHOLE CELL;

ADJUVANT; CYTOKINE; NANOPARTICLE; WHOLE CELL TUMOR VACCINE;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; NANOPARTICLES; RANDOM ALLOCATION;

EID: 84881666896     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.07.020     Document Type: Article

References (29)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. Ca Cancer J Clin 2011, 61:69-90.
2. Monsuez J.J., Charniot J.C., Vignat N., Artigou J.Y. Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010, 144:3-15.
3. Kayl A.E., Meyers C.A. Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Curr Opin Obstet Gynecol 2006, 18:24-28.
4. Attar E.C., Ervin T., Janicek M., Deykin A., Godleski J. Diagnosis in oncology - side effects of chemotherapy - case 3. Acute interstitial pneumonitis related to gemcitabine. JClin Oncol 2000, 18:697-698.
5. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
6. Weiss E.M., Wunderlich R., Ebel N., Rubner Y., Schlucker E., Meyer-Pittroff R., et al. Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Front Oncol 2012, 2:132.
7. Finn O.J. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003, 3:630-641.
8. Ribas A., Butterfield L.H., Glaspy J.A., Economou J.S. Current developments in cancer vaccines and cellular immunotherapy. JClin Oncol 2003, 21:2415-2432.
9. Berzofsky J.A., Terabe M., Oh S.K., Belyakov I.M., Ahlers J.D., Janik J.E., et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. JClin Invest 2004, 113:1515-1525.
10. Maher J., Davies E.T. Targeting cytotoxic T lymphocytes for cancer immunotherapy. Brit J Cancer 2004, 91:817-821.
11. Zhong Z.H., Wei X., Qi B.W., Xiao W.J., Yang L., Wei Y.Q., et al. Anovel liposomal vaccine improves humoral immunity and prevents tumor pulmonary metastasis in mice. Int J Pharmaceut 2010, 399:156-162.
12. Gilbert A.E., Karagiannis P., Dodev T., Koers A., Lacy K., Josephs D.H., et al. Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. Plos One 2011, 6:e19330.
13. Chiang C.L.L., Kandalaft L.E., Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 2011, 30:150-182.
14. Tabi Z., Man S. Challenges for cancer vaccine development. Adv Drug Deliver Rev 2006, 58:902-915.
15. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
16. Van Tendeloo V.F.I., Van Broeckhoven C., Berneman Z.N. Gene-based cancer vaccines: an exvivo approach. Leukemia 2001, 15:545-558.
17. Soiffer R., Hodi F.S., Haluska F., Jung K., Gillessen S., Singer S., et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. JClin Oncol 2003, 21:3343-3350.
18. Palmer K., Moore J., Everard M., Harris J.D., Rodgers S., Rees R.C., et al. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum Gene Ther 1999, 10:1261-1268.
19. Yue H., Wei W., Fan B., Yue Z., Wang L., Ma G., et al. The orchestration of cellular and humoral responses is facilitated by divergent intracellular antigen trafficking in nanoparticle-based therapeutic vaccine. Pharmacol Res 2012, 65:189-197.
20. Lutz M.B., Kukutsch N., Ogilvie A.L.J., Rossner S., Koch F., Romani N., et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. JImmunol Methods 1999, 223:77-92.
21. Lindberg S., Copolovici D.M., Langel Ü. Therapeutic delivery opportunities, obstacles and applications for cell-penetrating peptides. Ther Deliv 2011, 2:71-82.
22. Sethuraman V.A., Bae Y.H. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. JControl Release 2007, 118:216-224.
23. Li L.H., Guo K., Lu J., Venkatraman S.S., Luo D., Ng K.C., et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials 2008, 29:1509-1517.
24. Schwartzentruber D.J. Guidelines for the safe administration of high-dose interleukin-2. JImmunother 2001, 24:287-293.
25. Ali O.A., Huebsch N., Cao L., Dranoff G., Mooney D.J. Infection-mimicking materials to program dendritic cells in situ. Nat Mater 2009, 8:151-158.
26. Heath W.R., Carbone F.R. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001, 19:47-64.
27. Li H.Y., Li Y.H., Jiao J., Hu H.M. Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat Nanotechnol 2011, 6:645-650.
28. Joshi M.D., Unger W.J., Storm G., van Kooyk Y., Mastrobattista E. Targeting tumor antigens to dendritic cells using particulate carriers. JControl Release 2012, 161:25-37.
29. Zhang Z., Tongchusak S., Mizukami Y., Kang Y.J., Ioji T., Touma M., et al. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 2011, 32:3666-3678.